Zurück
www.microcapmarkets.com/...20&market=OTCBB&ticker=ADLS
Anzeige
Meldung des Tages: „Echte Revolution“: Dieses MedTech-Unternehmen greift nach dem Milliardenmarkt
Advanced Life Sciences Hldgs
Beiträge:
64
Zugriffe: 10.246 / Heute: 3
Zugriffe: 10.246 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +61,04%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +58,93%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +58,89%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +51,40%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +49,01%
finance.yahoo.com/news/...-prnews-4282019356.html?x=0&.v=1
at Northwestern's Technological Institute:
news.medill.northwestern.edu/chicago/news.aspx?id=158455
news.medill.northwestern.edu/chicago/news.aspx?id=158455
Quartalzahlen 4.Q 2009 und für das gesamte Jahr 2009 - Thursday, March 11, 2010 at 9:00 a.m. (EST).
A press release reporting the 2009 fourth quarter and full year results will be issued before the U.S. stock markets open on Thursday, March 11, 2010.
finance.yahoo.com/news/...-prnews-3968080849.html?x=0&.v=1
A press release reporting the 2009 fourth quarter and full year results will be issued before the U.S. stock markets open on Thursday, March 11, 2010.
finance.yahoo.com/news/...-prnews-3968080849.html?x=0&.v=1
Targeted for Third Quarter 2010:
ir.advancedlifesciences.com/...e&ID=1401434&highlight=
ir.advancedlifesciences.com/...e&ID=1401434&highlight=
Termination of a Material Definitive Agreement, Results of
biz.yahoo.com/e/100311/adls.ob8-k.html
biz.yahoo.com/e/100311/adls.ob8-k.html
von der Biomedical Advanced Research and Development Authority (Barda) des US Department of Health and Human Services:
finance.yahoo.com/news/...s-prnews-545629449.html?x=0&.v=1
finance.yahoo.com/news/...s-prnews-545629449.html?x=0&.v=1
www.microcapmarkets.com/...76&market=OTCBB&ticker=ADLS
www.microcapmarkets.com/...81&market=OTCBB&ticker=ADLS
Aktienerhöhung von 125 auf 625 mio. Commons von 120 auf 620 mio - jederzeit vor dem 08.04.11.
finance.yahoo.com/news/...-prnews-3643713781.html?x=0&.v=1
finance.yahoo.com/news/...-prnews-3643713781.html?x=0&.v=1
- Änderungen im BoD
- R/S any time before April 8, 2011 at a specific ratio to be determined by the board of directors within a range from 1-for-2 to 1-for-30 as set forth below
biz.yahoo.com/e/100413/adls.ob8-k.html
- R/S any time before April 8, 2011 at a specific ratio to be determined by the board of directors within a range from 1-for-2 to 1-for-30 as set forth below
biz.yahoo.com/e/100413/adls.ob8-k.html
über In-Vitro-Studie bezüglich Restanza:
ir.advancedlifesciences.com/...e&ID=1415582&highlight=
Also so langsam ... immer nur ein bisschen ...
ir.advancedlifesciences.com/...e&ID=1415582&highlight=
Also so langsam ... immer nur ein bisschen ...
kommen Montag, 10.05.2010, 09:00 h EDT
ir.advancedlifesciences.com/...e&ID=1423360&highlight=
ir.advancedlifesciences.com/...e&ID=1423360&highlight=
app.quotemedia.com/quotetools/...p=null&webmasterId=100937
Form 8-K for ADVANCED LIFE SCIENCES HOLDINGS, INC
Entry into a Material Definitive Agreement, Results of Oper
Item 1.01. Entry into a Material Definitive Agreement.
Advanced Life Sciences Holdings, Inc. (the "Company") entered into a letter agreement, effective as of May 6, 2010, with The Leaders Bank ("Leaders"), amending its line of credit in order to extend the maturity date by one year to January 1, 2012 (the "Amendment"). Under the terms of the Amendment, the Company is required to reduce the outstanding loan balance by $1.5 million immediately, $1.5 million by July 1, 2010 and an additional $1.0 million by April 2011. Dr. Michael T. Flavin, the Company's Chief Executive Officer, will provide a personal guarantee for the line of credit until the payment due July 1, 2010 is made. The Amendment also provides that the interest rate on the outstanding loan balance will increase from 8.5% to 10.0%, and the Company's rights as a result of its license agreement for cethromycin with Abbott Laboratories were included in the collateral for the line of credit. The Company agreed to issue Leaders 500,000 warrants to purchase shares of its common stock at the current public trading price per share on the date the final loan documents are delivered and an additional 500,000 warrants on the anniversary of that date.
In addition, on May 7, 2010, the Company entered into an agreement with Dr. Flavin providing that the $2 million promissory note with Dr. Flavin will be exchanged for equity securities of the Company (the "Debt Exchange Agreement"). The exchange is expected to occur at the same price and time as a contemplated concurrent sale of equity securities and will result in cancellation of the outstanding indebtedness.
The Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Debt Exchange Agreement is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein. The above descriptions of the material terms of the Amendment and the Debt Exchange Agreement do not purport to be complete and are qualified in their entirety by reference to Exhibit 10.1 and Exhibit 10.2.
Item 2.02. Results of Operations and Financial Condition.*
On May 10, 2010, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2010. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
10.1 Letter agreement between Advanced Life Sciences Holdings, Inc. and The
Leaders Bank, effective as of May 6, 2010.
10.2 Debt Exchange Agreement dated as of May 7, 2010.
99.1* Press Release dated May 10, 2010.
biz.yahoo.com/e/100510/adls.ob8-k.html
Entry into a Material Definitive Agreement, Results of Oper
Item 1.01. Entry into a Material Definitive Agreement.
Advanced Life Sciences Holdings, Inc. (the "Company") entered into a letter agreement, effective as of May 6, 2010, with The Leaders Bank ("Leaders"), amending its line of credit in order to extend the maturity date by one year to January 1, 2012 (the "Amendment"). Under the terms of the Amendment, the Company is required to reduce the outstanding loan balance by $1.5 million immediately, $1.5 million by July 1, 2010 and an additional $1.0 million by April 2011. Dr. Michael T. Flavin, the Company's Chief Executive Officer, will provide a personal guarantee for the line of credit until the payment due July 1, 2010 is made. The Amendment also provides that the interest rate on the outstanding loan balance will increase from 8.5% to 10.0%, and the Company's rights as a result of its license agreement for cethromycin with Abbott Laboratories were included in the collateral for the line of credit. The Company agreed to issue Leaders 500,000 warrants to purchase shares of its common stock at the current public trading price per share on the date the final loan documents are delivered and an additional 500,000 warrants on the anniversary of that date.
In addition, on May 7, 2010, the Company entered into an agreement with Dr. Flavin providing that the $2 million promissory note with Dr. Flavin will be exchanged for equity securities of the Company (the "Debt Exchange Agreement"). The exchange is expected to occur at the same price and time as a contemplated concurrent sale of equity securities and will result in cancellation of the outstanding indebtedness.
The Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Debt Exchange Agreement is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein. The above descriptions of the material terms of the Amendment and the Debt Exchange Agreement do not purport to be complete and are qualified in their entirety by reference to Exhibit 10.1 and Exhibit 10.2.
Item 2.02. Results of Operations and Financial Condition.*
On May 10, 2010, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2010. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
10.1 Letter agreement between Advanced Life Sciences Holdings, Inc. and The
Leaders Bank, effective as of May 6, 2010.
10.2 Debt Exchange Agreement dated as of May 7, 2010.
99.1* Press Release dated May 10, 2010.
biz.yahoo.com/e/100510/adls.ob8-k.html
mit grösserem Effekt als herkömmliche Antibiotika
www.prnewswire.com/news-releases/...inst-malaria-94911754.html
www.prnewswire.com/news-releases/...inst-malaria-94911754.html
um mit Restanza sexuell übertragbare Infektionen zu behandeln:
ir.advancedlifesciences.com/...e&ID=1432254&highlight=
ir.advancedlifesciences.com/...e&ID=1432254&highlight=
Advanced Life Sciences Offers Congressional Testimony on Critical Importance of Antibiotic Drug Development to Address Bacterial Resistance
ir.advancedlifesciences.com/...e&ID=1436482&highlight=
ir.advancedlifesciences.com/...e&ID=1436482&highlight=
wird das hier noch was ? Was ist das Problem hier,etwa der negative buchwert von ADLS,der durch die 12 Mio.-$ Schulden hervorgerufen wird ? Unglaublich,das "1 year target liegt bei 2$/share,aktueller Kurs 0,07$ !!
Ich wünsch dir was,meld dich mal wieder ?
P.S. Na,wer hatte Recht mit Genta von uns beiden ?!
MFG
Chali
Ich wünsch dir was,meld dich mal wieder ?
P.S. Na,wer hatte Recht mit Genta von uns beiden ?!
MFG
Chali
ir.advancedlifesciences.com/...e&ID=1443509&highlight=
über intravenöse Applikationen von Cethromycin:
ir.advancedlifesciences.com/...e&ID=1445582&highlight=
Restanza IV was administered as a single dose up to 60 mg/kg/day, the highest dose tested. Results demonstrated Restanza IV was well tolerated and generated 10-fold greater plasma exposure compared to oral administration. The studies were conducted in rats in accordance with good laboratory practices (GLP). The increased bioavailability of Restanza IV may allow for the treatment of serious hospital infections as well as the treatment of bioterror pathogens, such as anthrax, plague and tularemia after signs and symptoms are present.
"Restanza has potential to be the first ketolide antibiotic to have an intravenous formulation available in the U.S.," said Michael T. Flavin, Ph.D., Chairman and CEO. "Having an IV formulation allows for the potential treatment of serious hospital infections with an opportunity for an IV-to-pill switch as the patient moves from an in-patient setting to an outpatient setting. This is a significant feature that enhances the overall Restanza value proposition for physicians and patients."
Urgent Market Need for Potent Hospital-Based IV Antibiotics
There is an urgent market need in the U.S. and worldwide to identify and rapidly develop novel, safe and effective antibiotics that can overcome resistance to currently available drugs and that can be used in a variety of settings, such as an IV treatment in the hospital, and an IV-to-pill switch for stabilized patients and an oral treatment for outpatients.
Ketolide antibiotics, which represent a newer and promising class of therapeutics with greater potential against bacterial strains that are resistant to macrolides and penicillins, are typically very difficult to formulate in a clinically viable IV formulation due to low water solubility. Advanced Life Sciences has achieved a major breakthrough by successfully developing an IV formulation of Restanza. The formulation can be stored in a stable powder form and reconstituted on site in the hospital. The key features of this formulation support developing Restanza IV for use in the hospital setting.
The next step in the program is to initiate additional IND-directed preclinical studies of the Restanza IV formulation to support future Phase I clinical trials in normal healthy volunteers to evaluate its safety and pharmacokinetics.
ir.advancedlifesciences.com/...e&ID=1445582&highlight=
Restanza IV was administered as a single dose up to 60 mg/kg/day, the highest dose tested. Results demonstrated Restanza IV was well tolerated and generated 10-fold greater plasma exposure compared to oral administration. The studies were conducted in rats in accordance with good laboratory practices (GLP). The increased bioavailability of Restanza IV may allow for the treatment of serious hospital infections as well as the treatment of bioterror pathogens, such as anthrax, plague and tularemia after signs and symptoms are present.
"Restanza has potential to be the first ketolide antibiotic to have an intravenous formulation available in the U.S.," said Michael T. Flavin, Ph.D., Chairman and CEO. "Having an IV formulation allows for the potential treatment of serious hospital infections with an opportunity for an IV-to-pill switch as the patient moves from an in-patient setting to an outpatient setting. This is a significant feature that enhances the overall Restanza value proposition for physicians and patients."
Urgent Market Need for Potent Hospital-Based IV Antibiotics
There is an urgent market need in the U.S. and worldwide to identify and rapidly develop novel, safe and effective antibiotics that can overcome resistance to currently available drugs and that can be used in a variety of settings, such as an IV treatment in the hospital, and an IV-to-pill switch for stabilized patients and an oral treatment for outpatients.
Ketolide antibiotics, which represent a newer and promising class of therapeutics with greater potential against bacterial strains that are resistant to macrolides and penicillins, are typically very difficult to formulate in a clinically viable IV formulation due to low water solubility. Advanced Life Sciences has achieved a major breakthrough by successfully developing an IV formulation of Restanza. The formulation can be stored in a stable powder form and reconstituted on site in the hospital. The key features of this formulation support developing Restanza IV for use in the hospital setting.
The next step in the program is to initiate additional IND-directed preclinical studies of the Restanza IV formulation to support future Phase I clinical trials in normal healthy volunteers to evaluate its safety and pharmacokinetics.
aber warum steht ADLS nicht im FDA-Calendar für 2010 ? Wann kommt denn das NDA ?
Kommt es überhaupt ?
MFG
Zuki
Kommt es überhaupt ?
MFG
Zuki
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem ADVANCED LIFE SCIENC Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 63 | Advanced Life Sciences Hldgs | Fratze | Menne | 08.10.10 14:12 |